Literature DB >> 27699024

Intratumoral hemorrhage-related differences in the expression of vascular endothelial growth factor, basic fibroblast growth factor and thioredoxin reductase 1 in human glioblastoma.

Bulent Kaya1, Onur Çiçek2, Fatih Erdi1, Siddika Findik3, Yasar Karatas1, Hasan Esen3, Fatih Keskin1, Erdal Kalkan1.   

Abstract

The present study was designed to evaluate the expression of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and thioredoxin reductase 1 (TrxR1) in glioblastoma multiforme (GBM) with and without intratumoral hemorrhage. Surgically resected human GBM samples from 20 patients who underwent surgery at our institute were extracted from the histopathological specimens and divided into two groups. A total of 10 samples from each type of GBM (World Health Organization grade IV, intratumoral hemorrhage-positive or -negative) were included in each group. VEGF, bFGF and TrxR1 expression was analyzed using immunohistochemistry and the results were compared between groups. VEGF and bFGF immunoreactivity was significantly higher in GBMs containing intratumoral hemorrhage. Furthermore, VEGF, bFGF and TrxR1 immunointensity was significantly higher in GBMs containing intratumoral hemorrhage. Thus, the present study demonstrated a higher VEGF, bFGF and TrxR1 expression in GBMs contain intratumoral hemorrhage, indicatiogn a role of VEGF, bFGF and TrxR1 expression in the promotion of tumoral angiogenesis and tumoral growth by complex mechanisms that require further elucidation.

Entities:  

Keywords:  basic fibroblast growth factor; glioblastoma multiforme; hemorrhage; intratumoral; thioredoxin reductase 1; vascular endothelial growth factor

Year:  2016        PMID: 27699024      PMCID: PMC5038173          DOI: 10.3892/mco.2016.974

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  20 in total

1.  Correlation of bFGF, FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas.

Authors:  X W Bian; L L Du; J Q Shi; Y S Cheng; F X Liu
Journal:  Anal Quant Cytol Histol       Date:  2000-06       Impact factor: 0.302

2.  Immunohistochemical expression of cycloxygenase-2 in astrocytoma: correlation with angiogenesis, tumor progression and survival.

Authors:  Mona El-Sayed; Mahmoud M Taha
Journal:  Turk Neurosurg       Date:  2011-01       Impact factor: 1.003

3.  Ki-67 immunoreactivity, basic fibroblastic growth factor (bFGF) expression, and microvessel density as supplementary prognostic tools in low-grade astrocytomas. An immunohistochemical study with special reference to the reliability of different Ki-67 antibodies.

Authors:  Sverre H Torp; Mirjam Alsaker
Journal:  Pathol Res Pract       Date:  2002       Impact factor: 3.250

4.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

Authors:  J Holash; P C Maisonpierre; D Compton; P Boland; C R Alexander; D Zagzag; G D Yancopoulos; S J Wiegand
Journal:  Science       Date:  1999-06-18       Impact factor: 47.728

5.  Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance.

Authors:  Atsuko Hara; Isao Okayasu
Journal:  Acta Neuropathol       Date:  2004-04-16       Impact factor: 17.088

Review 6.  Angiogenesis and its role in the behavior of astrocytic brain tumors.

Authors:  Shirley I Stiver
Journal:  Front Biosci       Date:  2004-09-01

7.  Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma.

Authors:  Farhan Fateh Jang; Wang Wei; Wang Mao De
Journal:  J Ayub Med Coll Abbottabad       Date:  2008 Apr-Jun

Review 8.  Angiogenesis in malignant gliomas.

Authors:  K H Plate; W Risau
Journal:  Glia       Date:  1995-11       Impact factor: 7.452

9.  Relationship between expression of vascular endothelial growth factor and intratumoral hemorrhage in human pituitary adenomas.

Authors:  Young Jin Kim; Choong Hyun Kim; Jin Hwan Cheong; Jae Min Kim
Journal:  Tumori       Date:  2011 Sep-Oct

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  2 in total

1.  Thioredoxin Reductase Inhibitors as Potential Antitumors: Mercury Compounds Efficacy in Glioma Cells.

Authors:  Vanessa Pires; Isabella Bramatti; Michael Aschner; Vasco Branco; Cristina Carvalho
Journal:  Front Mol Biosci       Date:  2022-06-23

2.  Thioredoxin System Protein Expression Is Associated with Poor Clinical Outcome in Adult and Paediatric Gliomas and Medulloblastomas.

Authors:  Anqi Yao; Sarah J Storr; Khaled Al-Hadyan; Ruman Rahman; Stuart Smith; Richard Grundy; Simon Paine; Stewart G Martin
Journal:  Mol Neurobiol       Date:  2020-05-16       Impact factor: 5.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.